Basic Information
 |
Name:Prof. Oladapo B. CAMPBELL |
Faculty: CLINICAL SCIENCES |
|
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
Department:Radiation Oncology |
|
|
Brief Biography: |
Responsibility: |
Resume
|
NAME |
POSITION/TITLE |
|
Campbell Oladapo Babatunde |
Head of Department/ Professor & Consultant Radiation Oncologist. |
EDUCATION/TRAINING
|
INSTITUTION AND LOCATION |
DEGREE |
MM/YY |
FIELD OF STUDY |
|
|
1. ROSTOV-ON-DON MEDICAL INSTITUTE, RUSSIA. 2.Institute of Radiotherapeutics & Oncology, Glasgow Scotland 3. University of Edinburgh, Scotland
4. International Atomic Energy Agency Certificate in Nuclear Medicine, Moscow Russia 5. World Health Organisation Certificate in Molecular Biology, Lyon France 6. Fellowship West African College of Surgeons 7. Medical College of Radiologists (Nigeria) 8. International Atomic Energy Agency Fellowship Award for Course at Cairo Egypt. 9. Royal College of Radiologists, London, U.K. 10.International Atomic Energy Agency (I.A.E.A) Fellowship at Manchester, U.K. 11.European Society for Therapeutic Radiology and Oncology (ESTRO) Fellowship for Course on Radiation Physics for Radiotherapy. Leuven Belgium. 12.Shell Nigeria Petroleum Ltd. Fellowship for Conference on Cancer by the Estro in Malmo Sweden. 13.Nucletron International. Netherlands Travel Fellowship for Conference on Stereostatic Radiotherapy, Amsterdam,
14.International Atomic Energy Agency Fellowship for Conference at Vienna,
1. Ghana Atomic Energy Commission Fellowship for Workshop on Cancer Programme for Ghana. Accra Ghana.
1. Smithkline Beecham Travel 1996 Fellowship for Cancer Course of Therapeutic Radiology and Oncology, Berlin. 1. International Atomic Energy Agency Fellowship for Conference on Radiosensitizer in Management of Advanced Cancer of Uterine Cervix. (i) Kyoto, Japan – January 1995 (ii) Vienna - November 1997 (iii) Istanbul, Turkey – June 1999
18 International Atomic Energy Agency (IAEA) Fellowship at Accra Ghana 1. May & Baker Travel Fellowship to Conference of American Society of Clinical Oncology – New Orleans 1. International Atomic Energy Agency (IAEA) Fellowship for Conference on, USA. 2. International Atomic Energy Agency (IAEA) Fellowship for Conference on Vienna Austria.
1. International Atomic Energy Agency Fellowship for a scientific meeting on Vienna Austria.
|
MD Cert. Diploma (DMRT) Cert. in Nuclear Medicine Cert in Molecular Biology FWACS FMCR Cert. Cert. Cert. Cert. Cert. Cert. Cert. Cert. Cert. Cert. Cert. Cert. Cert. Cert. Cert. |
1974 1978 1980 1983 1990 1986 1995 1988 May 1991 June 1991 Sept. 1991 Sept. 1992 May 1993 Sept. 1993 Nov. 1995 Oct. 1996 Oct 2003 June 2004 Jan. 2005 Jan. 2006 June 2012 |
Medicine Radiotherapeutics & Oncology Medical Radiotherapy Nuclear Medicine Molecular Biology Radiotherapy Radiotherapy Brachytherapy of Cancer of the Cervix Malignant Lymphoma Computed Assisted Planning for Radiotherapy of the Head & Neck. Radiation Physics for Radiotherapy Cancer Management Stereostatic Radiotherapy Radiotherapy of Head and Neck Cancer Cancer Programme Therapeutic Radiology and Oncology Radiosensitizer in the Management of Advanced Cancer of Uterine Cervix. Management of Cancer in Africa Clinical Oncology Global Approach to Management of Breast Cancer in Developing Country Resource Sparing Treatment of Breast Cancer Resource Sparing Treatment of Breast Cancer in Developing Countries -
|
|
|
Positions and Honor |
||||
|
Member, Nigerian Medical Association |
1974 to date |
|||
|
Chairman, Nigerian Cancer Society, Oyo State |
1988 – 1990 |
|||
|
Visiting Consultant in Radiotherapy and Oncology to Lagos University Teaching Hospital |
1989 – 1990 |
|||
|
Consultant to Ahmadu Bello University Teaching Hospital on Radiotherapy and Oncology Centre Project |
November 1990 – 1991 |
|||
|
Member, Federal Minister of Health Advisory Committee on Re-Assessment of Ahmadu Bello University Teaching Hospital, Zaria, Centre of Excellence for Oncology and Radiotherapy, |
May 1990 - 1991 |
|||
|
Chief Scientific Investigator to International Atomic Energy Agency, Vienna. On Cancer. |
1993 to date |
|||
|
Member, Royal College of Radiologists, London U.K. |
1980 to date |
|||
|
Member, Association of Radiologists of West Africa (ARAWA) |
1980 to date |
|||
|
National Executive Member and Zonal Co-ordinator, Nigerian Cancer Society |
1990 to date |
|||
|
.Chief Scientific Investigator in Nigeria to International Atomic Energy Agency on Radiosensitizer on Management of Cancer of Uterine Cervix |
1995 -1999 |
|||
|
Co-ordinator, Cancer Counselling Clinic, University College Hospital Ibadan |
1992 to date |
|||
|
Member, New York Academy of Science |
1997 to date |
|||
|
.Member of the Senate, University of Ibadan |
2000 to date |
|||
|
President, Association of Radiologists of West Africa |
2005 to date |
|||
|
.Member, National Consultative Committee on Control of Cancer |
July 2006 to date |
|||
|
Mission Expert on Radiation Oncology to International Atomic Energy Agency Vienna |
2011 to date. |
|||
Researches
RESEARCH
Completed
RADIATION DOSIMETRY IN RADIOTHERAPY
COMPARATIVE EVALUATION OF HYPOFRACTIONATED
RADIOTHERAPY VERSUS CONVENTIONAL RADIOTHERAPY IN MANAGEMENT OF CERVICAL CANCER IN NIGERIANS: In Nigeria and sub-Saharan West Africa, cervical cancer is the commonest gynaecological tumour and accounts for 62.7% of all malignancies seen at the University College Hospital (UCH), Ibadan. Four hundred and eighty patients who attended the Radiotherapy clinic at the UCH were diagnosed with cervical cancer while there was only one functioning Radiotherapy facility – the Telecobalt Theratron 780C. The large influx of patients requiring radiation therapy during the period of study led to the need to introduce hypofractionated radiotherapy in order to maximise the use of the only available treatment facility during the stated period. Four hundred and eighty patients with histological diagnosis of cancer of the cervix were prospectively randomised into the study. 230 patients (study group) received hypofractionated (alternate days) external radiotherapy while 250 patients received conventional daily external radiotherapy. The results of this research study confirmed that while early radiation adverse effects, complete response, partial response and local tumour control rates were similar in the two groups, more marked late radiation adverse effects were observed in patients who received hypofractionated radiotherapy. The conclusion of this research study is that hypofractionated radiotherapy in the management of cervical cancer as is currently being carried out in some radiotherapy centres in Nigeria is contraindicated in view of marked late radiation morbidity associated with this treatment modality. Conventional Radiotherapy is the preferred treatment of choice while efforts should be made to procure more radiotherapy facilities for our cancer centres.
ONCOLOGY
CLINICAL APPLICATION OF AK2123 RADIOSENSITIZER IN THE MANAGEMENT OF ADVANCED CERVICAL CANCER IN NIGERIANS: Despite the recent improvements in radiotherapeutic techniques, 20 – 30% of patients with locally advanced cervical cancer have loco-regional failure. Hence 5 year survival rates for FIGO (International Federation of Obstetricians and Gyneacologists) staging for stages III and IV of cervical cancer are still put at 28% and 10% respectively. The failure of radiation therapy to control large pelvic masses may be related to the relative radioresistance of hypoxic cells within the tumour. Most tumours contain hypoxic cells, which are 2.5 – 3 times more resistant to radiation than aerobic cells. Our strategy in this research study was to create a high degree of oxygenation in tumour by using hypoxic cell radiosensitizers with high electron affinity, which mimics oxygen in biological medium. Unlike most hypoxic cell sensitizers, such as metronidazole, which will enhance radiosensitisation at a dosage, which will be highly toxic to peripheral and central nervous system, AK2123, Sanazole, an acetamide which is also a hypoxic cell sensitizer does not cause neurotoxicity at curative dose. In this study, 71 patients with histologically confirmed carcinoma of the cervix in stages IIIa and IIIb were prospectively randomised to receive AK2123, External Radiotherapy and intracavitary radioactive Caesium therapy (study group) while the control group patients received only External Radiotherapy and intracavitary radioactive Caesium therapy. The results of this research study reveal that there is improved complete response and local tumour control in patients on AK2123 and radiotherapy. AK2123 was also well tolerated by patients and has the potential to increase the radiation effect in hypoxic cells, effecting higher rates of local tumour control and disease free survival in patients with advanced cervical cancer. This research study, carried out between 1995 and 1999 was funded by the International Atomic Energy Agency, Vienna and is the first study in Africa to ascertain the therapeutic effect of this radiosensitizer in patients with advanced cervical cancer. As most of the patients who present with advanced carcinoma of the cervix are in the low socio-economic group, the cost and availability of this radiosensitizer will greatly influence its continuous use in our setting.
IN PROGRESS
ONCOLOGY
INDUCTION CHEMOTHERAPY AND CONCURRENT CHEMOTHERAPY IN MANAGEMENT OF ADVANCED HEAD AND NECK CANCER IN IBADAN.
“The story so far”
Cancer of the head and neck region constitute the third commonest malignancy seen and managed at the radiotherapy & Oncology centres in Nigeria (after cervical and breast cancers). Over 60% of these patients with this inoperable tumour present in advanced stages III and IV. Radiotherapy has been the main treatment modality for this cohort of patients with average of 6months – 1 year of remission post therapy. However, concurrent use of radiotherapy and chemotherapy could have a synergetic effect in that chemotherapy might increase the sensitivity of the tumour to radiation. Moreso, concurrent chemotherapy inhibits the repair of sublethal damage of tumour cells from radiation, synchronises cells to a particular radiosensitive phase of cell cycle and is cytotoxic in vitro. The objective of the research is to determine the therapeutic effect of induction chemotherapy and concurrent chemoradiation in a group of Nigerians with inoperable head and neck cancer.
Presently, 62 patients with inoperable squamous cell carcinoma of the head and neck have been prospectively randomised into this study. The control group patients receive only radiotherapy; while study group patients receive Cisplatinum based induction chemotherapy and concurrent chemoradiation (external daily radiotherapy pulsed with intravenous Methotrexate which is administered once in a week). The results are being studied for a definite write up.
CONCURRENT CHEMOTHERAPY WITH PELVIC IRRADIATION IN MANAGEMENT OF LOCALLY ADVANCED CERVICAL CANCER IN NIGERIAN.
“The story so far”
Radiation therapy has always been the treatment of choice for locally advanced cervical cancer. However, failure with irradiation has been reported in 40% of cases, particularly in patients with bulky tumours. In order to improve the local tumour control and treat distant subclinical metastases, chemotherapy was integrated with radiotherapy. Seventy four patients with locally advanced cervical cancer in stages IIb, IIIa, IIIb and IVb have been prospectively randomised into the study. The study group receive 2 courses of induction cytotoxic chemotherapy (Cisplatinum and 5 Fluorouracil) followed by external pelvic irradiation and thereafter Brachytherapy radioactive Caesium therapy. The aim of this research study is to ascertain the therapeutic effect of combined chemoradiation treatment modality in the management of locally advanced cervical cancer in Nigerians. Data collected is awaiting analysis.
BIOCHEMICAL PROFILE OF NIGERIAN PATIENTS WITH ADVANCED CERVICAL CANCER WHO HAD THERAPY WITH RADIOSENSITIZER AK2123 AND RADIOTHERAPY:
“The story so far”
In one of my completed research studies, Nigerian patients with advanced cervical carcinoma who had treatment with Radiosensitizer AK2123, and radiation therapy demonstrated better complete response rate, local tumour control and disease free survival rate than patients who had only radiotherapy (Completed research 2). Normal tissue (Nervous system, Urinary tract, Gastrointestinal tract, Haematopoietic system) in patients who had AK2123 Radiosensitizer suffered only mild to moderate degree (Grades 1-2) of toxicities in less than 40% of all the patients in this study group. However, biochemical profile in these patients on AK2123 has not been assessed. A normal biochemical profile coupled with mild to moderate degree of toxicities in normal tissues recorded will confirm that AK2123 as being well tolerated as acceptable for wide range use in management of patients with advanced cervical cancer. The data analysed from biochemical profile will definitely undergo a write up.
RESEARCH FOCUS
Clinical oncology is a vast area of medical science and is categorised into surgical oncology, gynaecological oncology, paediatric oncology, radiotherapy, genetic therapy of malignancies, psycho-oncology and medical oncology. The philosophy behind my research focus is how the findings from my research studies would be relevant to solving the contemporary problems in clinical oncology in our community. My research focus is hence in the three areas of clinical oncology – innovative radiotherapy, psycho-oncology and medical oncology (viral oncology).
Innovative radiation therapy involves the adaptation of available radiotherapeutic facilities where the contemporary radiotherapy facilities are not available. In Africa, comtemporary radiotherapeutic facilities are only available in South Africa and probably Egypt, the facilities in Nigeria are at best rudimentary and very few. With rising incidence of cancer diseases, I concentrated my research efforts on delivering novel approaches to tumour radiotherapeutic modalities through dosage response modulation and fractionations. Successes have been achieved with superficial malignant skin tumours with pioneer work on mycosis fungoides using low kilovolt0age 50kv and 1.25 megavoltage, the first time such therapy units are being used in the management of this lesion in Subsaharan West Africa (papers 1 and 4), these techniques are now extensively used in Africa and some other developing countries of the world. As a follow up to our research work on novel approaches to tumour radiotherapeutic modalities, I have collaborated with colleagues to establish the psycho-oncology clinic in the radiotherapy unit, UCH, Ibadan, the first of its kind in Subsaharan West Africa where cancer patients undergo counselling therapy, musculo-skeletal respiratory and audio-visual exercises to improve the coping habits of the patients to cancer disease and its complications. This therapy enhances the quality of life of these patients (papers 10, 11, 12, 13,14,15). Further work in these areas has led to the award of the first Ph.D. in Psycho-oncology of one of my students. Moreso, psycho-oncology is now firmly established as the 4th modality of therapy for cancer patients at the UCH, Ibadan (apart from surgery, radiotherapy & chemotherapy).
The incidence of HIV seropositivity in general Nigerian population is on the increase. Previous studies in Nigeria on the association of HIV with malignancies has been few but have yielded interesting results. Okpalla et al revealed that only 1% of cancer patients were found positive for HIV. I pioneered the first research study, which determined the prevalence of human immunodeficiency virus antibody among cancer patients undergoing radiotherapy, and assessed the prognosis (22). In our study, 3.6% of the patients were seropositive for HIV, which is similar to the HIV seropositivity of 4% in the general Nigerian population. Our study also confirmed that cancer patients are not at a higher risk of developing HIV seropositivity or AIDS disease than in the general Nigerian population.
MAJOR CONFERENCES ATTENDED WITH PAPERS READ
CAMPBELL O.B., ADU F.D., DANWATTA F.D.
PAPER READ: “HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY IN CANCER PATIENTS UNDERGOING RADIOTHERAPY IN IBADAN: CLINICAL FINDINGS, PATHOGENESIS AND THERAPY”. ASSOCIATION OF RADIOLOGISTS OF WEST AFRICA. PORTHARCOURT CONFERENCE. FEBRUARY 1997.
CAMPBELL O.B., AROWOJOLU A., AKINLADE B.I., ILESANMI A.O., ADEWOLE I.F.
PAPER READ: CLINICAL APPLICATION OF RADIOSENSITIZER (AK 2123) IN THE TREATMENT OF CANCER OF THE UTERINE CERVIX IN NIGERIA. INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA. NOVEMBER 3RD – 5TH 1997.
CAMPBELL O.B., AROWOJOLU A., BABARINSA A.
PAPER READ: CHEMOSENSITIZATION IN THE MANAGEMENT OF ADVANCED CANCER IN NIGERIA. INDIAN SOCIETY FOR HYPERTHEMIC ONCOLOGY AND RADIOTHERAPY. PURI QRRISA, INDIA 6TH - 9TH FEBRUARY 1998.
CAMPBELL O.B., GEORGE A.O., FASHIKA O.M.
PAPER READ: THE ROLE OF MEGAVOLTAGE 1.25MEV COBALT THERAPY IN THE MANAGEMENT OF KELOIDS. ASSOCIATION OF RADIOLOGISTS OF WEST AFRICA CONFERENCE. LAGOS. APRIL 1998.
CAMPBELL O.B., ADEOSUN A.B., AROTIBA J.T., AKINLADE B.I., OBED R.I.
PAPER READ: THE MANAGEMENT OF MALIGNA NT
TUMOURS OF THE MAXILLARY ANTRUM IN IBADAN – A REVISIT. WEST AFRICAN COLLEGE OF SURGEONS ANNUAL CONFERENCE KUMASI GHANA. FEBRUARY 2000.
NTEKIM A., CAMPBELL O. B. ET AL. DOCETAXEL IN THE MANAGEMENT OF BREAST CANER I- NIGERIANS. 42ND ANNUAL CONFERENCE OF ASSOCIATION OF RADIOLOGISTS OF WEST AFRICA. ENUGU. JUNE 2004.
WEST AFRICAN COLLEGE OF SURGEONS ANNUAL CONFERENCE, SENEGAL DAKAR. JULY 2011.
Publications
CHAPTER IN BOOKS ALREADY PUBLISHED
TEXTBOOK: COMPREHENSIVE GYNEACOLOGY IN THE TROPICS
EDITORS: E. Y. KWAWUKUME & E.E. EMMVEYAN & AUTHOR: CAMPBELL O. B. - PRINCIPLES OF RADIATION THERAPY AND CHEMOTHERAPY IN GYNEACOLOGICAL CANCER. PAGES 365 – 394.
Innovative radiation therapy
OLADAPO B. CAMPBELL: THE ROLE OF LOW KILOVOLTAGE (50KV) X - RAY BEAM THERAPY IN THE MANAGEMENT OF LOCALISED MYCOSIS FUNGOIDES. NIGERIAN QUARTERLY JOURNAL OF HOSPITAL MEDICINE 1984; 2:15 – 20.
CAMPBELL O. B., GEORGE A. O., SHOKUNBI W. A., AKANG E.E.U., AGHADUINO P.U.: PROBLEMS IN THE MANAGEMENT OF MYCOSIS FUNGOIDES IN NIGERIANS. TROPICAL AND GEOGRAPHICAL MEDICINE, JOURNAL OF ROYAL TROPICAL INSTITUTE, AMSTERDAM 1991; 43: 317 – 322.
CAMPBELL O. B., GEORGE A. O., FASIKA O.M: THE ROLE OF TELECOBALT MEGAVOLTAGE IRRADIATION IN THE MANAGEMENT OF KELOIDS IN IBADAN. NIGERIAN ORIENT JOURNAL OF MEDICINE. ACCEPTED FOR PUBLICATION 1998 JULY 15TH.
COMMENTS : In the management of skin tumours viz mycosis fungoides, Keloids, squamous and basal cell carcinoma, electron beam, 100kv and 300kvbeam therapies which are not deeply penetrating are employed. However, none of these facilities, though available are functioning in Nigeria.
In 1981, I innovated the use of 50Kv therapy beam in the management of mycosis fungoides with complete response and in 1990, with appropriate skin bolusing, I innovated the use of 1.25Mev Telecobalt beam therapy in management of various skin tumours.
These innovated radiotherapy techniques are new in clinical radiotherapy practice in Nigeria and Ghana.
RADIATION DOSIMETRY AND RADIOTHERAPY OF BREAST CANCER
CAMPBELL O. B., ADENIRAN S.A.M., OGUNDIMU A.O., ADENIPEKUN A., SAIDU O.: RADIATION DOSE IN RADIOTHERAPY OF CANCER OF THE BREAST FROM PRESCRIPTION TO DELIVERY. THE NIGERIAN EXPERIENCE. INTERNATIONAL ATOMIC ENERGY AGENCY JOURNAL .IAEA-TECDOC 1994; 734: 351-357.
CAMPBELL O.B., AGWIMAH R., ODUOLA B.I., ALAWALE A.: RADIOTHERAPY MANAGEMENT OF BREAST CANCER IN 400 NIGERIANS. NIGERIAN MEDICAL JOURNAL. ACCEPTED FOR PUBLICATION 1998 OCTOBER 19TH.
COMMENTS: Cancer of the breast is the second commonest female malignancy in the sub-Saharan West African after cancer of the cervix. Manual planning dosimetry had been employed in the pre-radiotherapy planning of these patients with adverse radiation effects - as recorded in our study (4) computerized treatment planning pre-radiotherapy was recommended. The result of the prospective randomised study on 400 Nigerian breast cancer patients (5) revealed that patients who received conventional and hypofractionated radiotherapy had similar response rate, local tumour control, and symptom free survival, with minimal morbidity of normal tissue. Hypofractionated radiotherapy which will enhance accommodation of more patients for radiotherapy has therefore been recommended as the therapeutic technique of breast cancer in order to optimise the few available radiotherapeutic facilities in our community.
GYNAECOLOGICAL & VIRAL ONCOLOGY
CAMPBELL O.B., AROWOJOLU A.O., ADU F.D., ADENIPEKUN A. AND OJENGBEDE O.A.: HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY IN PATIENTS WITH CANCER OF THE UTERINE CERVIX UNDERGOING RADIOTHERAPY: CLINICAL STAGES HISTOLOGICAL GRADE AND OUTCOME OF RADIOTHERAPY. JOURNAL OF OBSTETRICS AND GYNAECOLOGY 1999; VOL. 19, NO. 4: 403-405.
CAMPBELL O.B,., AROWOJOLU A.O. AKINLADE B.I., ADENIPEKUN A .O. AND BABARINSA I.A.: ADVANCED CERVICAL CARCINOMA IN IBADAN, NIGERIA: AN APPRAISAL OF RADIATION THERAPY. JOURNAL OF OBSTETRICS AND GYNAECOLOGY 2000 VOL 20 NO 6: 624-627 (ACCEPTED FOR PUBLICATION ON 5TH JUNE, 2000).
BABARINSA I.B., CAMPBELL O.B., ADEWOLE I.F.: PYOMETRIA COMPLICATING CANCER OF THE CERVIX. INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS 1999; 64: 75-76.
CAMPBELL O.B., AKINLADE I.B., AROWOJOLU A., BABARINSA I.A., AGWIMAH R.I., ADEWOLE I.F.: COMPARATIVE EVALUATION OF HYPOFRACTIONATED RADIOTHERAPY AND CONVENTIONAL FRACTIONATED RADIOTHERAPY IN THE MANAGEMENT OF CANCER OF THE CERVIX IN IBADAN, NIGERIA. AFRICAN JOURNAL OF MEDICINE AND MEDICAL SCIENCES VOL 29, NOS 3 & 4 , 2000 SEPT/DEC.: 253 – 258.
CAMPBELL O.B., ADU F.D., DANWATTA F.D.: HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY IN CANCER OF THE CERVIX PATIENTS UNDERGOING RADIOTHERAPY: CLINICAL FINDINGS PATHOGENESIS AND THERAPY. NIGERIAN MEDICAL JOURNAL 1997; 32(3): 90-93.
COMMENTS: Cancer of the uterine cervix is the commonest female genital tract malignancy at the University College Hospital, Ibadan. We researched into various factors associated with this disease and its management (6,7,8, 9, 10). Findings from our studies reveal that the incidence of HIV seropositivity in patients with this disease was the same as in the normal Nigerian population, though, HIV seropositive cancer patients had a shorter period of remission than HIV negative cancer of uterine cervix patients. There was no effect of radiotherapy on the HIV seropositivity in the patients at the radiation level of doses used (6,10).
Our study (9) revealed that though hypofractionated radiotherapy will maximise the use of few available therapy facilities (accommodate more patients), the high level of normal tissue morbidity makes it an undesirable treatment. Conventional daily radiotherapy remains the preferred therapy.
External Radiotherapy has always been the mainstay therapy for advanced cervical cancer with poor response and survival (7). This study reviewed other therapeutic options such as chemo-radiation therapy which yielded improved response and survival rates. Pyometria is a complication of cancer of the cervix in our environment. In assessing the benefits of pyometria drainage in this disease it was concluded that the procedure should be flexible, although it is preferred to evacuate vaginally.
OHEARI J.U., CAMPBELL O.B., ENYIDAH S.N.: PSYCHOSOCIAL EXPERIENCE BY CANCER PATIENTS RECEIVING RADIOTHERAPY AT IBADAN. NIGERIAN MEDICAL JOURNAL 1992; 23.2: 74-76.
OHEARI J.U., CAMPBELL O.B., LOLA O. DARE: THE EMOTIONAL DISPOSITION OF TERMINALLY ILL NIGERIAN PATIENTS TO THEIR CONDITION. ORIENT JOURNAL OF MEDICINE 1993; 5.4:115-117A.
OHEARI J.U., CAMPBELL O.B., ADENIPEKUN A.A.: THE OPINION OF TERMINALLY ILL NIGERIANS IN HOSPITAL CARE AND EUTHANASIA. NIGERIAN MEDICAL JOURNAL 1995; 28.2: 65-69.
OHEARI J.U., CAMPBELL O.B., ILESANMI A.O., OHEARI B.M.: PSYCHOSOCIAL CONCERNS OF NIGERIAN WOMEN WITH BREAST AND CERVICAL CANCER. PSYCHO-ONCOLOGY 1998; 7: 497-501.
OHEARI J.U., CAMPBELL O.B., ILESANMI A.O., OMIGBODUN A.O.: THE PSYCHOSOCIAL BURDEN OF CARING FOR SOME NIGERIAN WOMEN WITH BREAST CANCER AND CERVICAL CANCER. SOCIAL SCIENCE & MEDICINE 1999; 49: 1541-1549.
OHEARI J.U., CAMPBELL O.B., OHEARI B.M.: THE OPINION OF CAREGIVERS OF SOME WOMEN WITH BREAST AND CERVICAL CANCER IN SOME ASPECTS OF THE DISEASE. WEST AFRICAN JOURNAL OF MEDICINE 1999; 18.1: 6-12.
COMMENTS: I collaborated with other researchers in establishing the first cancer counselling clinic based at the Radiotherapy unit, University College Hospital, Ibadan. All our research studies were focussed on psycho-social aspects of cancer patients management (psycho-oncology) (11, 12, 13, 14, 15, 16). Our studies assessed the psychosocial stresses experienced by cancer patients undergoing radiotherapy and emotional disposition of terminally ill Nigerian patients to their condition. Evaluation of how our cancer patients coped with these conditions are presented. It was confirmed that a substantial number of Nigerian patients would react maturely to the issue of euthanasia (11, 12, 13). An insight was carried out into the psychosocial concerns and burdens of patients with breast and cervical cancer and the care givers (14, 15, 16). Psychic stresses which the patients and care giver undergo are presented and the studies address how they (patients and caregivers) cope with the psycho-social burdens.
GENERAL ONCOLOGY AND RADIOTHERAPY
CAMPBELL O.B.:MARJOLIN’S ULCER OF THE SCALP. NIGERIAN MEDICAL PRACTIONER 1981; 2. 3/4: 65-66.
KEKERE-EKUN T.A., CAMPBELL O.B., NWOKU A.L.: EXPERIENCES WITH IRRADIATION OF INOPERABLE OROFACIAL TUMOURS. NIGERIAN MEDICAL PRACTITIONER 1984; 8.3: 53-55.
OGUNLEYE O.T., OHWOVORIOLE A.E., CAMPBELL O.B.: USE OF TECHNITIUM-99M UPTAKE STUDIES IN THE RAPID ASSESSMENT OF THYROID FUNCTION. EAST AFRICAN MEDICAL JOURNAL 1986; 63: 571-576.
DUROSINMI-ETTI F.A., CAMPBELL O.B.: COMBINATION CHEMOTHERAPY AS THE FIRST LINE IN THE MANAGEMENT OF LOCALLY ADVANCED EPIDERMOID CARCINOMA OF HEAD AND NECK REGION IN NIGERIANS. AFRICAN JOURNAL OF MEDICINE AND MEDICAL SCIENCES 1990; 17.4: 221-225.
AKEN’OVA Y.A., CAMPBELL O.B.: THE EFFICACY OF SPLENIC IRRADIATION AND CHEMOTHERAPY IN THE MANAGEMENT OF CHRONIC MYELOGENOUS LEUKAEMIA AMONG NIGERIANS. NIGERIAN JOURNAL OF MEDICAL SCIENCES 1991; 2: 49-51.
AJAIYEOBA J.A., AKANG E.E.U., CAMPBELL O.B., OLURIN J.O., AGHADUINO P.U.: RETINOBLASTOMA IN IBADAN: TREATMENT AND PROGNOSIS. WEST AFRICAN JOURNAL OF MEDICINE 1993; 12: 223-227.
CAMPBELL O.B., ELUMELU T.N., DANWATTA F.D.: EVALUATION OF THE EFFICACY AND TOLERABILITY OF TROPISETRON (NAVOBAN) IN THE PREVENTION OF CANCER CHEMOTHERAPY INDUCED NAUSEA AND VOMITING. NIGERIAN MEDICAL PRACTITIONER 1994; 28: 3-4.
CAMPBELL O.B., ADENIPEKUN A., SAIDU O.: COMPARISON OF ANTI-EMETIC EFFICACY OF ONDANSETRON WITH METOCLOPRAMIDE IN RADIOCHEMOTHERAPEUTIC MANAGEMENT OF MALIGNANT TUMOURS. NIGERIAN MEDICAL JOURNAL 1994; 26(2): 61-63.
ADENIPEKUN A., AMANOR-BOADU S.D., SOYANWO O.A., CAMPBELL O.B., OYESEGUN A.R.: COMPLICATIONS FOLLOWING SEDATION OF PAEDIATRIC ONCOLOGY PATIENTS UNDERGOING RADIOTHERAPY. WEST AFRICAN JOURNAL OF MEDICINE 1998; 17(4): 224-226.
AKANG E.E.U., AJAIYEOBA L.A., CAMPBELL O.B., OLURIN I.O., AGHADUINO P.U.: RETINOBLASTOMA IN IBADAN NIGERIA: 11-CLINICOPATHOLOGIC FEATURES. WEST AFRICAN JOURNAL OF MEDICINE 2000; 19(1): 6-10.
OLUWATOSIN O.M., ASHAYE O.A., ADEKUNLE O.O., CAMPBELL O.B.: THE TEMPORALIS MUSCLE PLUS GLABELLAR FLAP: HANDY LOCAL FLAPS FOR ORBITAL REPAIR AFTER EXENTERATION. WEST AFRICAN JOURNAL OF MEDICINE 2000; 14(2): 160-161.
CAMPBELL O.B., ADEOSUN A.B., AROTIBA J.T., AKINLADE B.I., OBED R.I.: MANAGEMENT OF MALIGNANT TUMOURS OF THE MAXILLARY ANTRUM IN IBADAN, NIGERIA – A REVISIT. NIGERIAN JOURNAL OF CLINICAL PRACTICE 2000; 3(1): 1-4.
CAMPBELL O.B.: RADIOTHERAPY IN CANCER MANAGEMENT. DOKITA ONCOLOGY EDITION 1998; 25.1: 35-39.
SHOKUNBI W.A., CAMPBELL O.B., OGUNBIYI J.O.: MALIGNANT HAEMANGIOENDOTHELIOMA OF THE BONE IN A HBSC DISEASE PATIENT – A CASE REPORT. AFRICAN JOURNAL OF MEDICINE AND MEDICAL SCIENCES 1996; 25: 293-296.
IHEKWABA F. N., LADIPO J.K., CAMPBELL O.B.: FIBROUS HISTIOCYTOMAS IN THE TROPICS. JOURNAL OF THE ROYAL COLLEGE OF SURGEONS OF EDINBURGH 1992 : 165 – 168.
NTEKIM A, ABDULLAHI ADAMU, AJEKIGBE R., CAMPBELL. O. B.; DOXETACEL IN THE MANAGEMENT OF BREAST CANCER IN NIGERIANS. A PILOT STUDY WEST AFRICAN JOURNAL OF RADIOLOGY 2000.
COMMENTS: Management of cancer patients should be by multidisciplinary approach. I embarked upon multidisciplinary research studies (with surgeons, gynaecologists, Nuclear physicists and haematologist). Study 17 highlights the need for oncologist to monitor benign diseases associated with malignant lesions, while study 19 confirm the role of radioactive technetium – 99m in the assessment of thyroid function. Results from my other collaborative studies 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, confirm that combined therapy modalities (with surgery, radiotherapy and chemotherapy) is the preferred and beneficial treatment modality with improved response and survival rates for majority of cancer patients in our environment.
ADENIPEKUN A, SOYANWO O. A, ARMANOR BOADU S.B, CAMPBELL. O. B. OYESEGUN R. (1998) COMPLICATIONS FOLLOWING SEDATION OF PAEDIATRIC ONCOLOGY PATIENTS UNDERGOING RADIOTHERAPY WEST AFRICAN JOURNAL OF MEDICINE 17. 224-224.
ADENIPEKUN A, CAMPBELL O.B, OYESEGUN A.R, ELUMELU T.N. (2002). RADIOTHERAPY IN THE MANAGEMENT OF EARLY BREAST CANCER IN NIGERIA: OUTCOME OF CHEST WALL IRRADIATION ALONE IN CLINICAL NODES FREE AXILLA. AFRICAN JOURNAL OF MEDICINE AND MEDICAL SCIENCES 31:345-347.
ADENIPEKUN A., ALONGE T.O., CAMPBELL O.B., ELUMELU T. N. (2002). THE MANAGEMENT OF METASTATIC BONE PAIN IN DEVELOPING COUNTRY - THE ROLE OF RADIOTHERAPY AS AN ADJUVANT TO WEAK OPIODS INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 56:40-43.
ADEBAMOWO C.A., OGUNDIRAN T.O., ADENIPEKUN A.A., OYESEGUN R, CAMPBELL O. AKANG E.E.U, ROTIMI C, OLOPADE O.I (2003). OBESITY AND HEIGHT IN URBAN NIGERIAN WOMEN WITH BREAST CANCER. ANNALS OF EPIDEMIOLOGY (EAP) 13:455-461.
MALOMO A.O., OWOEYE O, ELUMELU T.N., AKANG E.E.U, ADENIPEKUN A. A,, CAMPBELL O. B, SHOKUNBI T.M. (2005). EFFECT OF DEXAMETHAZONE METRONIDIZOLE AND ASCORBII ACID ON THE MORPHOLOGICAL CHANGES INDUCED BY GAMMA RAYS ON THE SPINAL CORD OF WISTAR RATS. AFRICAN JOURNAL OF MEDICINE AND MEDICAL SCIENCES 34:161-165.
ADEBAMOWO C.O., OGUNDIRAN R.O., ADENIPEKUN A, OYESEGUN R. CAMPBELL O.B, AKANG E.E.U DASS, OLOPADE O.I (2005) COMPLETE ALLELIC ANALYSIS OF BRCA 1 AND 2 VARIOUS IN YOUNG BREAST CANCER PATIENTS OF AFRICAN ANCESTRY. JOURNAL OF MEDICAL GENETICS 42:276-281.
ELUMELU T.N., OLANIYI J.A, SHOKUMBI W.A, CAMPBELL O.B. 2001) A REVIEW OF THE EFFECT OF PALLIATIVE RADIOTHERAPY IN THE MANAGEMENT OF MULTIPLE MYELOMA PATIENTS ON STANDARD CHEMOTHERAPY AT THE UCH IBADAN. NIGERIAN JOURNAL OF CLINICAL PRACTICE 4:69-71.
CAMPBELL O. B. PROFESSIONALISM - BUILDING AN ENDURING ORGANISATION. NATIONAL POSTGRADUATE COLLEGE OF NIGERIA FACULTY LECTURE 11/09/07. PROCEEDIDNGS OF 2007 FACULTY OF RADIOLOGY LECTURE.
GEORGE A.O., OGUNBIYI A.O DARAMOLA.O.O, CAMPBELL.O.B. (2005) ALBINISM AMONG NIGERIAN WITH MALIGNANT MELAMONA. TROP.DOC.VOL.35:55-556.
DAWOTOLA D. A., ODIGIE V.J., YUSUFU L.M.D, ADAMU A., ABU P., JIMOH A. O., MAHMUD M.D., AJEKIGBE A.T., CAMPBELL O.B. (2011). EXTERNAL RADIOTHERAPY IN METASTATIC BONE PAIN FROM SOLID TUMOURS IN ZARIA, NIGERIA. NIGERIAN JOURNAL OF SURGERY. VOL. 17 NO. 1: 11-14.
ADEWUYI D.A., AROGUNDADE R., IGASHI J.B., CHOM N.D., HAMIDU A.U., CAMPBELL O.B., THE PATTERN OF CHEST RADIOGRAPHS FINDINGS IN METASTATIC CANCER PATIENTS SEEN IN TERTIARY HOSPITAL IN NORTHERN NIGERIA. THE NIGERIAN POSTGRADUATE MEDICAL JOURNAL, VOL. 18, NO. 4:245-250.
NTEKIM A.I., ABDULLAHI A., CAMPBELL O. B., ADENIPEKUN A., AJEKIGBE A: DOCETAXEL CHEMOTHERAPY IN THE MANAGEMENT OF ADVANCED AND METASTATIC BREAST CANCER IN NIGERIA: A PILOT STUDY. WEST AFRICAN JOURNAL OR RADIOLOGY VOL 8 [1] 25 -28 2001.
NTEKIM AI, CAMPBELL OB: PRIMARY LYMPHOMA OF THE LIVER IN A CERVICAL CANCER SURVIVOR- A CASE REPORT. THE TROPICAL JOURNAL OF HEALTH SCIENCES 2009; 16 (1): 44-46.
NTEKIM A. I, NUHU FT, CAMPBELL OB. BREAST CANCER IN YOUNG FEMALES IN IBADAN – NIGERIA. AFRICAN HEALTH SCIENCES 2009, 9: (4); 242-246.
NTEKIM A I, ADAMU ABDULHAHI AJEKIGBE A, CAMPBELL OB. BURKITTS LYMPHOMA- 50 YEARS AFTER DISCOVERY- REVIEW ARTICLE. WEST AFRICAN JOURNAL OF RADIOLOGY, 2009: 16 (1); 55-60 .
ATARA NTEKIM, ADENIYI ADENIPEKUN, BIDEMIAKINLADE AND OLADAPO CAMPBELL. HIGH DOSE RATE BRACHYTHERAPY IN THE TREATMENT OF CERVICAL CANCER: PRELIMINARY EXPERIENCE WITH COBALT 60 RADIONUCLIDE SOURCE – A PROSPECTIVE STUDY. CLINICAL MEDICINE INSIGHTS: ONCOLOGY 2010; 4: 89-94.
- N. ELUMELU, A. A. ADENIPEKUN, A. A. ABDUL-SALAM, A.D. BOJUDE, O. B. CAMPBELL: QUALITY OF LIFE IN PATIENTS WITH HEAD AND NECK CANCER ON RADIOTHERAPY TREATMENT AT IBADAN. RESEARCGER 3(8). 1 – 10 (ISSN: 1553-9865).
TEN PUBLICATIONS WHICH BEST REFLECT MY CONTRIBUTION TO SCHOLARSHIP AND RESEARCH
GROUP I – Innovative Radiotherapy and Radiation Dosimetry
CAMPBELL O.B., GEORGE A.O., SHOKUNBI W.A., AKANG E.E.U., AGHADIUNO D.U.: Problems in the management of mycosis fungoides in Nigeria. Tropical and Geographical Medicine Journal of Royal Tropical Institute, Amsterdam 1991; 43(3): 317-322. This research work uses megavoltage 1.25 cobalt unit through dosage response modulations and fractionations in treatment of mycosis fungoides. This is the first of such research work in Subsaharan Africa and this therapy facility is being extensively used in Nigeria in treatment of this tumour when conventional therapy units such as electron beam therapy, 100kv and 300kv which are ideally suitable for treating these skin lesions are not functioning or not available.
OLADAPO CAMPBELL: The role of low kilovoltage (50kv) x-ray therapy in the management of localised mycosis fungoides. Nigerian Quarterly Journal of Hospital Medicine 1984; 2(4): 15-20.
This paper reported a novel approach to the radiotherapeutic treatment of mycosis fungoides using low kilovoltage radiation. The good response with this radiotherapeutic facility had led to its use when there is non-availability of contemporary therapy facilities.
CAMPBELL O.B., ADENIRAN S.A.M., OGUNDIMU A.O., ADENIPEKUN A., SAIDU O.: Radiation dose in radiotherapy of cancer of the breast from prescription to delivery. The Nigerian experience. International Atomic Energy Agency Journal 1994; IAEA-TECDOC-734: 351-357.
This research reports radiation dosimetry by manual approach, which has resulted in high rate of treatment failure- viz; local tumour recurrence and high rate of early and late radiation adverse effects following radiotherapy for breast cancer patients. The superiority and the need to acquire treatment planning system in the management of these patients to reduce rate of treatment failure and radiation adverse effects were emphasised in this study.
This study resulted in the first computerisation of the treatment planning system of radiotherapy centre in Nigeria by International Atomic Energy Agency, Vienna.
CAMPBELL O.B., AGWIMAH R., ODUOLA B.I., ALAWALE A.: Radiotherapy management of breast cancer in 400 Nigerians. Nigerian Medical Journal. Accepted for publication 1998, October 19th. I consider this work as one of the best that reflects my contribution to research. the work was problem solving. Between 1988 and 1992, the radiotherapy unit, university college hospital, Ibadan, was the only functioning radiotherapy centre in Anglophone West Africa with only one therapy unit – Telecobalt Theratron 780-C, 1.25Mev. 5,000 cancer patients were treated between 1988 and 1992 and breast cancer was one of the commonest malignancies. This huge influx of patients resulted in long waiting period for therapy with the resultant progression of cancer disease. This deplorable situation provoked me to evolve the first hypofractionated radiotherapy of breast cancer patients in West Africa. Between 1988 and 1992, 400 breast cancer patients were prospectively randomised to two treatment groups: the control group patients received conventional daily fractionated radiotherapy while the study group received alternate days (hypofractionated) radiotherapy. The introduction of this treatment (hypofractionated radiotherapy) technique has reduced the waiting period for radiotherapy from 3 months to 6 weeks, it has produced the same rate of loco-regional disease recurrence and symptom free interval as conventional fractionated radiotherapy. In the different radiotherapy centres in Nigeria, because of the need to maximise the use of the few existing therapy facilities, hypofractionated radiotherapy of breast cancer is now being administered in management of these patients.
GROUP II – Psycho - Oncology
OHAERI, J.U., CAMPBELL O.B.: Psychosocial stresses experienced by cancer patients receiving radiotherapy at Ibadan. Nigerian Medical Journal 1992; 23: 74-79. In collaboration with other researchers, I set up the first psycho-oncology clinic in Subsaharan West Africa for cancer patients undergoing radiotherapy. This paper compared the severity of symptoms of psychic distress (anxiety and depression), adequacy of care by relations, knowledge of the illness, psychological reaction to the illness and physical and social problems being encountered as a result of the cancer disease in patients undergoing radiotherapy and those not yet subjected to radiotherapy. The study revealed similar social and clinical characteristics in both groups. The study revealed that adequate community care of cancer should include strengthening the resources of the traditional extended family system, which will enable the patient to cope with the psychosocial stresses.
OHEARI J.U., CAMPBELL O.B., ILESANMI A.O., OHEARI B.M.: Psychosocial concerns on Nigerian women with breast and cervical cancer. Psycho-oncology 1998; 7: 47-50. In oncology practice in Nigeria, there is paucity of institutional facilities for care and a dearth of specialist manpower with barely 20 doctors (i.e. surgeons and radiotherapists) attending to 100,000 new cancer patients annually. In each situation, there is hardly enough time for the doctor to focus on the bare symptoms and signs of the illness so that complaints in the psycho-social domain have little chance of receiving attention. This study profers solution to this problem.
GROUP III – Viral Oncology
CAMPBELL O.B., ADU F.D., DANWATTA F.D.: Human immunodeficiency virus antibody in cancer patients undergoing radiotherapy: Clinical findings, pathogenesis and therapy. Nigerian Medical Journal 1997; 32(3): 90-92.
This is the first study in radiation oncology and virology, which confirmed that cancer patients who had HIV seropositivity pre-radiotherapy remain seropositive post radiotherapy. The study also revealed that 3.6% of cancer patients in this study were seropositive - a finding similar to that obtained in non-cancer populace. Moreso, findings from our study revealed that HIV positive cancer patients had a shorter period of remission than HIV negative cancer patients.
CAMPBELL O.B., AROWOJOLU A.O., ADU F.D., ADENIPEKUN A., OJENGBEDE O.A.: Human immunodeficiency virus antibody in patients with cancer of the uterine cervix undergoing radiotherapy: Clinical stages, histological grade and outcome of radiotherapy. Journal of Obstetrics and Gyneacology 1999; 19(4): 403-405.
This is the first time human immunodeficiency virus in patients with cancer of the cervix is being subjected to the effect of radiation in subsaharan West Africa. From this study, new findings which are immensely beneficial to viro-oncology practitioners have emerged: that cervical cancer patients are not at higher risk of acquiring the HIV virus than other members of the Nigerian general population but rather the presence of HIV antibody in this cancer patients denotes a rapid progression of cancer of the uterine cervix in such patients. Those cancer patients who were HIV positive seropositive had high grade disease.
GROUP IV – Chemo - Radiation Therapy
AKEN’OVA Y.A., CAMPBELL O.B.: The efficacy of splenic irradiation and chemotherapy in the management of chronic myelogenous leukaemia (CML) among Nigerians. Nigerian Journal of Medical Sciences 1991; 49-51. This study was carried out to assess the therapeutic efficacy of using chemotherapy (Busulphan and Endoxan) and splenic irradiation compared to using chemotherapy alone in patients with chronic myelogenous leukaemia (CML). The chemoradiation therapy of improved the mean survival to 53.3 months (median – 48.6 months) compared to 48.6 months (median - 38 months) using chemotherapy alone. Splenic irradiation resulted in marked reduction in splenic size with total disappearance of gastrointestinal symptoms. This was the first chemoradiation therapy of CML patients in Ibadan and is now administered in clinical practice.
DUROSINMI-ETTI F.A., CAMPBELL O.B.: Combination chemotherapy as the first line in the management of locally advanced epidermoid carcinoma of the head and neck region in Nigeria. African Journal of Medicine and Medical Sciences 1990; 17(4): 221-225. Over 70% of patients with head and neck tumours in Nigeria present in stages III and IV at first presentation. Radiotherapy which hitherto, had been the sole therapy for inoperable (advanced) head and neck cancer in Nigeria resulted in poor response and survival. This study was a novel study: induction chemotherapy (pre-radiotherapy) was for the first time carried out in Nigerian patients with these malignancies. This study using chemotherapy as first line of management - enhanced debulking of the tumour – making inoperable tumour amenable to surgery or radiation therapy. The patient also experienced psychological boost through the gradual reduction in tumour size. Induction chemotherapy for head and neck cancer is now in wide clinical application in Nigeria.
Contact Information
|
Phone: 08033657394 |
Address: |
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
|
Facebook: Profile Link |
LinkedIn: Profile Link |
Twitter: Profile Link |
|
Instagram: Profile Link |
YouTube: Profile Link |
Pinterest: Profile Link |